Suvorexant for Reduction of Delirium in Older Adults After Hospitalization
Suvorexant zur Verringerung von Delir bei älteren Erwachsenen nach Hospitalisierung
JAMA Network Open · 16.08.2024 · 7 (8) · e2427691
DOI: 10.1001/jamanetworkopen.2024.27691 ↗Auf einen Blick
In einer randomisierten Studie hatten unter Suvorexant weniger ältere Hochrisikopatient:innen ein Delir als unter Placebo. Der Unterschied war nicht statistisch signifikant.
Fragestellung
Verringert Suvorexant bei älteren, delirgefährdeten Erwachsenen nach Hospitalisierung das Delirrisiko im Vergleich zu Placebo?
Methode
Doppelblind, placebokontrollierte Phase-3-RCT in 50 Krankenhäusern in Japan; 1:1-Randomisierung zu Suvorexant 15 mg oder Placebo abends bis zu 7 Tage.
Ergebnisse
203 Teilnehmende: 17/101 (16,8 %) mit Delir unter Suvorexant vs. 27/102 (26,5 %) unter Placebo; Differenz −8,7 % (95 %-KI −20,1 % bis 2,6 %), P = .13. Unerwünschte Ereignisse ähnlich.
Schlussfolgerung der Autor:innen
In dieser randomisierten Studie hatten unter Suvorexant zwar weniger Teilnehmende ein Delir als unter Placebo, der Unterschied war jedoch nicht statistisch signifikant.
Kernaussagen
- Delir: 16,8 % unter Suvorexant vs. 26,5 % unter Placebo
- Differenz −8,7 % (95 %-KI −20,1 % bis 2,6 %), P = .13
- Unerwünschte Ereignisse waren in beiden Gruppen ähnlich
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 16.08.2024. Verfasst von Kotaro Hatta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Juntendo University Nerima Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Delirium, Hospitalization, Triazoles, Azepines. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Gerontologische Pflege, Delir
Abstract (Originalsprache)
Importance Delirium is common among older hospitalized adults. In addition to presenting immediate management issues, delirium can increase the long-term risk of dementia, institutionalization, and mortality. Delirium is associated with disrupted sleep, and prior studies suggest that some specific sleep-promoting agents may reduce delirium.
Objective
To evaluate the orexin receptor antagonist suvorexant for reducing delirium in older adults at high risk for delirium after hospitalization. Design, Setting, and Participants This double-blind, placebo-controlled, phase 3 randomized clinical trial was conducted at 50 hospitals in Japan between October 22, 2020, and December 23, 2022. The study population included Japanese adults aged 65 to 90 years who were at high risk for delirium (mild cognitive impairment or mild dementia, history of delirium at prior hospitalization, or both) and had been hospitalized for acute disease or elective surgery. Data analysis was performed between January 23 and March 13, 2023.
Intervention
Participants were randomized 1:1 to suvorexant (15 mg) or placebo taken at bedtime for up to 7 days while in the hospital. Main Outcomes and Measures Delirium, the primary end point, was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria while participants were hospitalized. The treatment difference in the proportion of participants with delirium was analyzed.
Results
This study included 203 participants: 101 were treated with suvorexant (mean [SD] age, 81.5 [4.5]; years; 52 men [51.5%] and 49 women [48.5%]) and 102 received placebo (mean [SD] age, 82.0 [4.9] years; 45 men [44.1%] and 57 women [55.9%]). There were 17 participants with delirium (16.8%) in the suvorexant group compared with 27 (26.5%) in the placebo group (difference, −8.7% [95% CI, −20.1% to 2.6%]; P = .13). Adverse events were similar between the 2 groups. Conclusions and Relevance In this randomized clinical trial of suvorexant in older adults at high risk for delirium after hospitalization, fewer participants taking suvorexant had delirium compared with placebo, but the difference was not statistically significant. Further studies are needed to determine whether suvorexant may be useful for reducing delirium, particularly delirium with a hyperactive component, in this population. Trial Registration ClinicalTrials.gov Identifier: NCT04571944
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Juntendo University Nerima Hospital, Tokyo, Japan.
- Department of Psychiatry, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan.
- Department of Psychiatry, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
- Department of Psychiatry, Tokyo Medical and Dental University Hospital, Tokyo, Japan.
- Department of Psychiatry and Psycho-Oncology, Fukuyama City Hospital, Fukuyama, Japan.
- Department of Psychiatry and Palliative Care, Tonan Hospital, Sapporo, Japan.
Zitieren
APA
Hatta, K., Kishi, Y., Wada, K., Takeuchi, T., Taira, T., Uemura, K., Ogawa, A., Takahashi, K., Sato, A., Shirakawa, M., Herring, W. J., Arano, I., & Suvorexant 085 Study Group (2024). Suvorexant for Reduction of Delirium in Older Adults After Hospitalization. JAMA Network Open, 7(8), e2427691. https://doi.org/10.1001/jamanetworkopen.2024.27691
Vancouver
Hatta K, Kishi Y, Wada K, Takeuchi T, Taira T, Uemura K, et al. Suvorexant for Reduction of Delirium in Older Adults After Hospitalization. JAMA Network Open. 2024;7(8):e2427691. doi:10.1001/jamanetworkopen.2024.27691
BibTeX
@article{Hatta2024,
author = {Hatta, Kotaro and Kishi, Yasuhiro and Wada, Ken and Takeuchi, Takashi and Taira, Toshihiro and Uemura, Keiichi and Ogawa, Asao and Takahashi, Kanae and Sato, Asako and Shirakawa, Masayoshi and Herring, W Joseph and Arano, Ichiro and Suvorexant 085 Study Group, Suvorexant 085 Study Group},
title = {Suvorexant for Reduction of Delirium in Older Adults After Hospitalization},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {8},
pages = {e2427691},
doi = {10.1001/jamanetworkopen.2024.27691}
}
EUVIMED